Combined Q-switched Nd:YAG Laser and Platelet Rich Plasma Versus Q- Switched Nd:YAG Laser Alone in Melasma

Combined Q-switched Nd:YAG Laser and Platelet Rich Plasma Versus Q- Switched Nd:YAG Laser Alone in the Treatment of Melasma: A Split Face Study.

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04765930

Enrollment

Registered

2021-02-23

Start date

2019-10-01

Completion date

2021-03-01

Last updated

2021-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperpigmentation, Lasers, Melasma, PRP

Keywords

laser toning, Hemi-MASI, Colorimeter, Erythema Index, Melanin Index

Brief summary

Melasma is a common, acquired, esthetically disfiguring hypermelanosis of the face. Melasma is considered a disappointing challenge when treatment options are addressed. Diverse treatment modalities such as retinoic acid, hypo-pigmenting agents like hydroquinone, azelaic acid, and kojic acid, chemical peels, microdermabrasion, and lasers have been tried for the treatment of melasma. There is no universally proven therapy that induces and maintains remission of the condition. Q-switched: Nd YAG laser toning and platelet rich plasma (PRP) are promising treatments for melasma.The aim of this work is evaluate the efficacy and safety of combined PRP and Q-switched: NdYAG laser in the treatment of melasma using clinical assessment, in addition to assessment of Melanin Index and Erythema Index.

Interventions

OTHERQ-switched nd:YAG laser toning

Q-switched nd:YAG laser toning for melasma.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Patients with bilateral nearly symmetric melasma on the face.

Exclusion criteria

* Patients receiving systemic or topical or laser treatment relevant to melasma within three months before enrollment into the study. * Use of oral or injectable contraceptives or hormone replacement therapy during treatment or 12 months before * Patients active skin infections and active HSV * History of hypertrophic scars or keloids. * Patients with hypercoagulable state or bleeding diatheses * Pregnant and lactating females. * History of liver diseases * Intake of systemic chemotherapy, corticosteroids, antiplatelets or anticoagulants

Design outcomes

Primary

Measure	Time frame	Description
Hemi-Melasma Area and Severity Index (MASI) score	2 months after final treatment	Hemi-Melasma Area and Severity Index(MASI) score for Pigmentation, and Area of involvement. The minimum value is 0 and the maximum value is 12. Higher scores mean a worse outcome.

Secondary

Measure	Time frame	Description
Melanin Index	2 months after final treatment	Objective assessment of melanin index using colorimeter apparatus. The minimum value is 0. No maximum value. Higher scores mean a worse outcome.
Erythema Index	2 months after final treatment	Objective assessment of erythema index using colorimeter apparatus. The minimum value is 0. No maximum value. Higher scores mean a worse outcome.

Other

Measure	Time frame	Description
Paients' Satisfaction assessed by the VAS	2 months after final treatment	a four-scale grading score: poor: response rate= 0-25%; fair: response rate= 25-50%; good: response rate=50-75%; excellent: response rate=75-100%

Countries

Egypt

Contacts

Primary ContactMona El-Kalioby, MD

mona.elkalioby@kasralainy.edu.eg+201224442941

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026